| 摘要 |
The disclosure relates to a family of nuclear transport modulators (CRM1 inhibitors) with a general formula (I) or a pharmaceutically acceptable salt thereof, wherein the values of the unspecified functional groups are described within the specification. The disclosure also relates to the use these compounds for the treatment of disorders such as proliferative disorder, an inflammatory disorder, an autoimmune disorder, a viral infection, an ophthalmological disorder, a neurodegenerative disorder, a disorder of abnormal tissue growth, a disorder related to food intake, allergies, cancer and a respiratory disorder and methods of manufacturing these compounds. |
